Skip to main content

Table 3 CBCT cortical and medullary lysis change (N = 14) and MRI change (N = 14) in patients after treatment

From: Mandibular involvement in SAPHO syndrome: a retrospective study

Treatmenta CT MRI
N Remissionb Progressionc N Muscle edema Subcutaneous soft tissue swelling Bone marrow edema Periosteitis Synovial thickening of TMJ
R S/P R S/P R S/P R S/P R S/P
TNFi 4 2 2 3 1 1 0 1 0 3 0 1 0 0
TNFi + CS 1 0 1 0
TNFi + MTX 0 3 1 2 0 1 1 2 0 0 0 0
TNFi + TwFH 0 1 0 1 0 0 0 1 0 0 0 0
BP 6 6 0 5 3 1 1 0 4 1 1 0 1 0
BP + CS 1 1 0 0
BP + TwFH 1 1 0 1 0 0 0 0 0 1 0 0 1 0
BP + TNFi 2 2 0 1 1 0 0 0 1 0 0 0 0 0
TwFH + CS 0 4 4 0 1 0 2 2 1 1 3 0
CS 2 0 2 3 2 1 1 0 2 1 0 0 1 1
CS + MTX 1 1 0 0
IL-6 inhibitor 1 0 1 0
  1. R remission, S/P stable disease/Progression, TNFi tumour necrosis factor-α inhibitor, MTX methotrexate, TwFH Tripterygium wilfordii Hook F, CS Corticosteroids, TMJ temporomandibular joint, BP bisphosphonate
  2. aOne patient could change the drug due to its uneffectiveness during the follow-up
  3. bRemission: a new or increased area of cortical or medullary lysis on CBCT, or a new or increased area or increased intensity of the high-intensity signal of bone marrow or surrounding soft tissue on the T2-weighted image
  4. cProgression: a decreased area of cortical or medullary lysis on CBCT, or a decreased area or intensity of the high-intensity signal of bone marrow or surrounding soft tissue on the T2-weighted image